A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

A new indication for omalizumab is prompting clinicians to adjust their approach to oral food challenges, but experts ...

Omalizumab, currently used to treat asthma, has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food ...

The FDA has approved Omlyclo (omalizumab-igec), the first interchangeable biosimilar to Xolair (omalizumab).

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert A. Wood, MD, FAAAAI, professor of pediatrics, Johns ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

Among these: CT-P39: In May 2024, this became the first omalizumab biosimilar approved in Europe, for use in omalizumab-refractory CSU, allergic asthma, and chronic rhinosinusitis with nasal polyps.

The study also found omalizumab helped in blocking reactions to not only peanuts, but to milk, eggs, wheat, cashews, walnuts, and hazelnuts. Omalizumab is also considered unique, as it is safe for ...

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with fewer side effects.

In a new study, omalizumab, an injectable drug for food allergies, performed better than oral immunotherapy. A subsequent phase of the study found that patients may be able to introduce allergenic ...

The study also found omalizumab helped in blocking reactions to not only peanuts but to milk, eggs, wheat, cashews, walnuts, and hazelnuts.